Base de dados : LILACS
Pesquisa : D06.472.699.631.525.425.875 [Categoria DeCS]
Referências encontradas : 264 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 27 ir para página                         

  1 / 264 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1171273
Autor: Pasqualini, Titania.
Título: Implicancias de la restricción de crecimiento intrauterino (RCIU) sobre las enfermedades metabólicas / Implications of the small for gestational age(SGA)over metabolic deseases
Fonte: Rev. Soc. Argent. Endocrinol. Ginecol. Reprod;16(1):15-25, mayo 2009. tab, graf.
Idioma: es.
Resumo: Definición: El niño con restricción del crecimiento intrauterino/pequeño para edad gestacional (RCIU/PEG) se define como aquel que nace con un peso (PN) y/o longitud corporal (LC) igual o menor a 2 desvíos standard (DS) debajo de la media de acuerdo a la edad gestacional. En algunas situaciones se define como aquellos que nacen con un peso menor de percentilo 10, corregido para edad gestacional. Crecimiento postnatal: Aunque el 87% de los niños nacidos con RCIU/PEG recuperan su peso/estatura antes de los dos años de edad; el 13% no desarrolla este crecimiento compensador. Algunos pueden recuperar estatura normal, pero a los 18 años alrededor del 7% queda definitivamente con una estura por debajo de -2 DS. Alteraciones metabólicas: La reprogramación fetal propone que la desnutrición intrauterina materno-fetal programa la actividad metabólica y hormonal del recien nacido. Estudios epidemiológicos mostraron que el tamaño al nacer puede asociarse con rápida ganancia de peso, mayor masa grasa con distribución visceral y obesidad a largo plazo. La conexión entre un medio ambiente perinatal adverso y las consecuencias observadas en la vida adulta podría ser una permanente reducción en la sensibilidad a la insulina. Se ha detectado tempranamente una resistencia a la insulina, preferentemente en aquellos que recuperaron muy rápidamente el peso o lo excedieron. El RCIU se ha asociado a mayor riesgo de síndrome metabólico con mayor tendencia a diabetes tipo II, dislipidemia, hipertensión, enfermedad cardiaca isquémica y accidentes cerebro vasculares. Existe también reprogramación del eje hipotálamo-hipófiso-adrenal y gonadal con aparición de pubarca precoz, hiperandrogenismo ovárico (PCO).
Descritores: Hormônio do Crescimento Humano/uso terapêutico
Recém-Nascido Prematuro/crescimento & desenvolvimento
Recém-Nascido/crescimento & desenvolvimento
-Doenças Metabólicas/epidemiologia
Insulina/efeitos adversos
Limites: Humanos
Recém-Nascido
Responsável: AR


  2 / 264 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: biblio-1165162
Autor: Bergadá Ignacio.
Título: Utilización de la hormona de crecimiento en niños y adolescentes / [Use of growth hormone in children and adolescents].
Fonte: Medicina (B.Aires);73(3):272-6, jun. 2013.
Idioma: es.
Resumo: Growth hormone treatment for children and adolescents with growth disorders has been used for more than five decades. Since 1985 recombinant human growth hormone (rhGH) is the only drug approved for treatment. In most of the countries rhGH is licensed for the treatment of children with growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic renal failure, and children born small for gestational age. The objective of the treatment is to improve the growth of these patients. The efficacy of rhGH treatment based on auxologic parameters has shown that growth response is variable and mostly dependent on each particular indication. Most of the reports on drug safety obtained from different databases that included thousands of patients, have shown that rhGH is a safe drug and that serious adverse events are rare. Regarding new indications to improve height in children, data on efficacy remains controversial, so we believe their ultimate indication must take into account potential risk versus benefits of this treatment.
Descritores: Hormônio do Crescimento Humano/uso terapêutico
-Adolescente
Criança
Desenvolvimento Infantil/efeitos dos fármacos
Hormônio do Crescimento Humano/deficiência
Humanos
Proteínas Recombinantes/uso terapêutico
Recém-Nascido Pequeno para a Idade Gestacional
Resultado do Tratamento
Síndrome de Prader-Willi/tratamento farmacológico
Síndrome de Turner/tratamento farmacológico
Transtornos do Crescimento/tratamento farmacológico
Tipo de Publ: Resumo em Inglês
Artigo de Revista
Responsável: AR5.1 - Centro de Gestión del Conocimiento y las Comunicaciónes


  3 / 264 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1058190
Autor: Hidalgo Santos, Antonio David; de Mingo Alemany, María del Carmen; Moreno Macián, Francisca; León Cariñena, Sara; Collado Ballesteros, Erika; Cañete Nieto, Adela.
Título: Efectos endocrinológicos tardíos del tratamiento oncológico en supervivientes de meduloblastoma / Endocrinological late effects of oncologic treatment on survivors of medulloblastoma
Fonte: Rev. chil. pediatr;90(6):598-605, dic. 2019. tab.
Idioma: es.
Resumo: INTRODUCCIÓN: La radioterapia, quimioterapia y la cirugía empleada en el tratamiento de los tumores cerebrales tienen efectos en el eje hipotálamo-hipofisario y pueden resultar en disfunción endocrina hasta en el 96% de los casos. PACIENTES Y MÉTODO: Estudio retrospectivo y descriptivo en pacientes diagnos ticados de meduloblastoma sometidos a tratamiento con quimio y radioterapia en los últimos 20 años en un hospital terciario. Se analizan variables edad, sexo, peso, talla, índice de masa corporal (IMC) al final del seguimiento, estadio de maduración sexual, niveles séricos de TSH y T4 libre, ACTH/cortisol e IGF-1, FSH, LH, estradiol, testosterona, perfil lipídico (colesterol total) y prueba de función dinámica de hormona de crecimiento. RESULTADOS: Muestra total de 23 pacientes. El déficit de hormona de crecimiento es la secuela más frecuente (82 %) seguido de disfunción ti roidea (44,8%) y disfunción puberal (24,1%). Solo se diagnosticó un caso de diabetes insípida y 2 casos de déficit de corticotrofina. CONCLUSIONES: El seguimiento a largo plazo de los supervivientes de meduloblastoma tratados con quimio y radioterapia revela una prevalencia muy alta de disfun ción endocrina, particularmente de deficiencia de hormona del crecimiento y de hipotiroidismo. Creemos oportuna la monitorización y el seguimiento a largo plazo de estos pacientes con el fin de garantizar un manejo terapéutico adecuado de aquellas disfunciones tratables.

INTRODUCTION: Radiation therapy, chemotherapy, and surgery used to treat brain tumors have effects on the hy pothalamic-pituitary-adrenal axis and can result in endocrine dysfunction in up to 96% of cases. PATIENTS Y METHOD: Retrospective and descriptive study in patients diagnosed with medulloblasto ma who underwent treatment with chemo and radiotherapy in the last 20 years in a tertiary hospital. The variables analyzed were age, sex, weight, height, body mass index (BMI) at the end of follow-up, sexual maturity stage, serum levels of TSH and free T4, ACTH/cortisol and IGF-1, FSH, LH, estradiol, testosterone, lipid profile (total cholesterol), and growth hormone dynamic function test. RESULTS: Total sample of 23 patients. Growth hormone deficiency is the most frequent sequelae (82%) fo llowed by thyroid dysfunction (44.8%), and disorders of puberty (24.1%). Only one case of diabetes insipidus and two cases of corticotropin deficiency were diagnosed. CONCLUSIONS: Long-term follow- up of medulloblastoma survivors treated with chemo and radiotherapy reveals a very high prevalence of endocrine dysfunction, especially growth hormone deficiency and hypothyroidism. We believe that monitoring and long-term follow-up of these patients is necessary in order to ensure adequate therapeutic management of those treatable dysfunctions.
Descritores: Neoplasias Cerebelares/terapia
Quimiorradioterapia/efeitos adversos
Meduloblastoma/terapia
-Puberdade Precoce/etiologia
Doenças da Glândula Tireoide/etiologia
Neoplasias Cerebelares/sangue
Estudos Retrospectivos
Hormônio Adrenocorticotrópico/deficiência
Hormônio do Crescimento Humano/deficiência
Diabetes Insípido/etiologia
Doenças do Sistema Endócrino/etiologia
Sobrepeso/etiologia
Sobreviventes de Câncer
Hipogonadismo/etiologia
Meduloblastoma/sangue
Limites: Humanos
Masculino
Feminino
Pré-Escolar
Criança
Responsável: CL1.1 - Biblioteca Central


  4 / 264 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-242600
Autor: Rivarola, Marco A; Belgorosky, Alicia.
Título: Uso de la hormona de crecimiento en pediatría / The use of growth hormone in pediatric patients
Fonte: Med. infant;6(1):40-43, mar. 1999.
Idioma: es.
Descritores: Hormônio do Crescimento Humano/deficiência
Hormônio do Crescimento Humano/uso terapêutico
Insuficiência de Crescimento/terapia
Síndrome de Turner/terapia
-Argentina
Limites: Humanos
Masculino
Feminino
Responsável: AR305.1 - SID - Servicio de Información y Documentación


  5 / 264 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-782156
Autor: Laway, Bashir; Misgar, Raiz; Mir, Shahnaz; Wani, Arshad.
Título: Clinical, hormonal and radiological features of partial Sheehan's syndrome: an Indian experience
Fonte: Arch. endocrinol. metab. (Online);60(2):125-129, Apr. 2016. tab.
Idioma: en.
Resumo: ABSTRACT Objective The objective of this study was to describe clinical presentation, hormonal profile and imaging characteristics of 21 patients with partial Sheehan’s syndrome. Subjects and methods This prospective study was carried out over a period of six years (2008-2013). The evaluation of patients included clinical assessment, hormone estimations and contrast enhanced magnetic resonance imaging of pituitary. Results We documented preservation of gonadotroph, corticotroph and lactotroph function in 71.4, 61.9, and 9.5% of patients respectively. Conclusion To conclude some of the pituitary functions can be preserved in Sheehan’s syndrome and this has important implications from the treatment and long term morbidity point of view.
Descritores: Adeno-Hipófise/fisiopatologia
Hormônios Hipofisários/sangue
Tiroxina/sangue
Hormônio do Crescimento Humano/sangue
Hipopituitarismo/sangue
Hipopituitarismo/diagnóstico por imagem
-Hormônios Hipofisários/deficiência
Valores de Referência
Tiroxina/deficiência
Hidrocortisona/deficiência
Hidrocortisona/sangue
Imagem por Ressonância Magnética
Estudos Prospectivos
Hormônio do Crescimento Humano/deficiência
Período Pós-Parto
Hemorragia Pós-Parto
Limites: Humanos
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  6 / 264 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-785227
Autor: Fideleff, Hugo L; Fideleff, Gabriel; Boquete, Hugo R; Suárez, Martha; Azaretzky, Miriam.
Título: Male-female differences in 6-sulfatoxymelatonin excretion in hypopituitary patients
Fonte: Arch. endocrinol. metab. (Online);60(3):223-230tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective To evaluate melatonin secretion in adult hypopituitary patients with Growth Hormone deficiency (AGHD) on and off replacement therapy. Subjects and methods We studied 48 subjects: 12 (6 males) untreated AGHD (AGHDnt), 20 (10 males) treated AGHD (AGHDt) and 16 healthy subjects (8 males) as control group (CG). We measured urinary 6-sulfatoxymelatonin (6-SM) in total (24 h samples), nocturnal (6-SMn): 1800-0800 and diurnal samples (6-SMd): 0800-1800. Results Significant differences were observed among the 3 groups of male subjects, in total 6-SM (p < 0.05), nocturnal 6-SM (p < 0.02) and nighttime-daytime delta values (p < 0.003). CG had significantly higher values than the AGHDnt in total 6-SM (p < 0.01), nocturnal 6-SM (p < 0.05) and nighttime-daytime delta values (p < 0.01). AGHDt patients showed significantly higher levels in nighttime-daytime delta values than AGHDnt patients (p < 0.05). In females, no significant differences were found among the 3 groups studied in total, nocturnal, diurnal or nighttime-daytime delta values. In males, significant correlations were found among total 6-SM (r = 0.58; p = 0.029), nocturnal 6-SM (r = 0.70; p = 0.006) and nighttime-daytime delta values (r = 0.71; p = 0.004) vs. serum IGF-1 levels in subjects evaluated. In females, significant correlations were found among total 6-SM (r = 0.57; p = 0.02) vs. serum IGF-1 levels in subjects evaluated. A tendency towards a significant correlation was found in diurnal 6-SM (r = 0.48; p = 0.07). Conclusions Our findings show a sexual dimorphism in 6-SM excretion in AGHD patients and provide an interesting approach to a further understanding of some chronobiological disorders involved in GH deficiency.
Descritores: Fatores Sexuais
Ritmo Circadiano/fisiologia
Hormônio do Crescimento Humano/deficiência
Melatonina/análogos & derivados
-Hipófise/fisiologia
Fator de Crescimento Insulin-Like I
Estudos de Casos e Controles
Estudos Prospectivos
Hipopituitarismo/fisiopatologia
Melatonina/metabolismo
Melatonina/urina
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Adulto Jovem
Responsável: BR1.1 - BIREME


  7 / 264 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Latronico, Ana Claudia
Texto completo
Id: biblio-827792
Autor: Ludwig, Natasha G; Radaeli, Rafael F; Silva, Mariana M X; Romero, Camila M; Carrilho, Alexandre J F; Bessa, Danielle; Macedo, Delanie B; Oliveira, Maria L; Latronico, Ana Claudia; Mazzuco, Tânia L.
Título: A boy with Prader-Willi syndrome: unmasking precocious puberty during growth hormone replacement therapy
Fonte: Arch. endocrinol. metab. (Online);60(6):596-600, Nov.-Dec. 2016. tab, graf.
Idioma: en.
Projeto: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Resumo: SUMMARY Prader-Willi syndrome (PWS) is a genetic disorder frequently characterized by obesity, growth hormone deficiency, genital abnormalities, and hypogonadotropic hypogonadism. Incomplete or delayed pubertal development as well as premature adrenarche are usually found in PWS, whereas central precocious puberty (CPP) is very rare. This study aimed to report the clinical and biochemical follow-up of a PWS boy with CPP and to discuss the management of pubertal growth. By the age of 6, he had obesity, short stature, and many clinical criteria of PWS diagnosis, which was confirmed by DNA methylation test. Therapy with recombinant human growth hormone (rhGH) replacement (0.15 IU/kg/day) was started. Later, he presented psychomotor agitation, aggressive behavior, and increased testicular volume. Laboratory analyses were consistent with the diagnosis of CPP (gonadorelin-stimulated LH peak 15.8 IU/L, testosterone 54.7 ng/dL). The patient was then treated with gonadotropin-releasing hormone analog (GnRHa). Hypothalamic dysfunctions have been implicated in hormonal disturbances related to pubertal development, but no morphologic abnormalities were detected in the present case. Additional methylation analysis (MS-MLPA) of the chromosome 15q11 locus confirmed PWS diagnosis. We presented the fifth case of CPP in a genetically-confirmed PWS male. Combined therapy with GnRHa and rhGH may be beneficial in this rare condition of precocious pubertal development in PWS.
Descritores: Síndrome de Prader-Willi/tratamento farmacológico
Puberdade Precoce/tratamento farmacológico
Hormônio Liberador de Gonadotropina/uso terapêutico
Hormônio do Crescimento Humano/uso terapêutico
-Síndrome de Prader-Willi/diagnóstico
Síndrome de Prader-Willi/genética
Puberdade Precoce/complicações
Proteínas Recombinantes/efeitos adversos
Proteínas Recombinantes/uso terapêutico
Metilação de DNA
Terapia de Reposição Hormonal/métodos
Limites: Humanos
Masculino
Criança
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  8 / 264 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887587
Autor: Rosario, Pedro Weslley; Calsolari, Maria Regina.
Título: Long-term follow-up of patients with elevated IGF-1 and nadir GH > 0 4 µg/L but < 1 µg/L
Fonte: Arch. endocrinol. metab. (Online);61(5):426-431, Sept.-Oct. 2017. tab.
Idioma: en.
Resumo: ABSTRACT Objective To report the results of initial investigation and after 5 years of patients with a suspicious clinical scenario for acromegaly, elevated IGF-1, and nadir GH during an oral glucose tolerance test (OGTT) > 0.4 µg/L but < 1 µg/L. Subjects and methods Seventeen patients who had elevated IGF-1 (outside puberty and pregnancy) in two measurements and GH between 0.4 and 1 µg/L during OGTT were selected. Results During initial assessment, only one patient had microadenoma on magnetic resonance imaging (MRI) of the pituitary. In this patient, IGF-1 returned to normal spontaneously after 5 years. In the remaining 16 patients, spontaneous normalization of IGF-1 was observed in four and IGF-1 continued to be elevated in 12 after 5 years. None of the latter patients developed a phenotype of acromegaly, changes in physiognomy or increase in IGF-1 and no tumor was detected by imaging methods. Two patients had nadir GH < 0.4 µg/L, while the nadir GH remained between 0.4 and 1 µg/L in 10 patients. Conclusion In patients (notably young adult or adult women) without a typical phenotype in whom IGF-1 is measured due to a suspicious clinical scenario and is found to be slightly elevated, even if confirmed and in the absence of other causes, a nadir GH cut-off value of 0.4 µg/L instead of 1 µg/L in the OGTT might be inadequate for the diagnosis.
Descritores: Neoplasias Hipofisárias/sangue
Acromegalia/sangue
Fator de Crescimento Insulin-Like I/análise
Adenoma/sangue
Hormônio do Crescimento Humano/sangue
-Fenótipo
Neoplasias Hipofisárias/diagnóstico por imagem
Fatores de Tempo
Imagem por Ressonância Magnética
Biomarcadores/sangue
Adenoma/diagnóstico por imagem
Seguimentos
Teste de Tolerância a Glucose
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Pessoa de Meia-Idade
Idoso
Adulto Jovem
Responsável: BR1.1 - BIREME


  9 / 264 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887591
Autor: Ribeiro-Oliveira Jr, Antonio; Barkan, Ariel.
Título: Biochemical diagnosis of acromegaly without a typical clinical phenotype: what are the concerns?
Fonte: Arch. endocrinol. metab. (Online);61(5):414-415, Sept.-Oct. 2017.
Idioma: en.
Descritores: Acromegalia
Hormônio do Crescimento Humano
-Fenótipo
Fator de Crescimento Insulin-Like I
Seguimentos
Limites: Humanos
Tipo de Publ: Comentário
Editorial
Responsável: BR1.1 - BIREME


  10 / 264 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-989290
Autor: Vasques, Gabriela A; Andrade, Nathalia L M; Jorge, Alexander A L.
Título: Genetic causes of isolated short stature
Fonte: Arch. endocrinol. metab. (Online);63(1):70-78, Jan.-Feb. 2019. tab, graf.
Idioma: en.
Projeto: São Paulo Research Foundation (FAPESP); . National Council for Scientific and Technological Development (CNPq); . Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES).
Resumo: ABSTRACT Short stature is a common feature, and frequently remains without a specific diagnosis after conventional clinical and laboratorial evaluation. Longitudinal growth is mainly determined by genetic factors, and hundreds of common variants have been associated to height variability among healthy individuals. Although isolated short stature may be caused by the combination of variants, with a deleterious impact on the growth of individuals with polygenic inheritance, recent studies have pointed out some monogenic defects as the cause of the growth disorder observed in nonsyndromic children. The majority of these defects are in genes related to the growth plate cartilage and in the growth hormone (GH) - insulin-like growth factor 1 (IGF-1) axis. Affected patients usually present the mildest spectrum of some forms of skeletal dysplasia, or subtle abnormalities of laboratory tests, suggesting hormonal resistance or insensibility. The lack of specific characteristics, however, does not allow formulation of a definitive diagnosis without the use of broad genetic studies. Thus, molecular genetic studies including panels of genes or exome analysis will become essential in investigating and identifying the causes of isolated short stature in children, with a crucial impact on treatment and follow-up.
Descritores: Variação Genética/genética
Estatura/genética
Fator de Crescimento Insulin-Like I/genética
Hormônio do Crescimento Humano/genética
Transtornos do Crescimento/genética
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME



página 1 de 27 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde